RIUZZI, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 4.135
AS - Asia 3.366
EU - Europa 2.873
SA - Sud America 641
AF - Africa 74
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.098
Nazione #
US - Stati Uniti d'America 4.044
SG - Singapore 1.503
BR - Brasile 523
HK - Hong Kong 518
IT - Italia 505
UA - Ucraina 472
IE - Irlanda 442
CN - Cina 440
RU - Federazione Russa 353
VN - Vietnam 270
KR - Corea 195
DE - Germania 191
SE - Svezia 179
FR - Francia 157
FI - Finlandia 137
GB - Regno Unito 117
IN - India 80
NL - Olanda 57
RO - Romania 56
TR - Turchia 52
CA - Canada 48
AT - Austria 44
BD - Bangladesh 44
IQ - Iraq 43
AR - Argentina 42
JP - Giappone 33
PL - Polonia 31
PH - Filippine 27
ES - Italia 25
CH - Svizzera 23
PK - Pakistan 23
CO - Colombia 21
BE - Belgio 20
MX - Messico 20
ZA - Sudafrica 20
CZ - Repubblica Ceca 18
EC - Ecuador 18
ID - Indonesia 17
UZ - Uzbekistan 16
SA - Arabia Saudita 14
MY - Malesia 13
VE - Venezuela 13
LB - Libano 11
CL - Cile 10
EG - Egitto 10
MA - Marocco 10
TN - Tunisia 9
IR - Iran 7
PY - Paraguay 7
JM - Giamaica 6
LT - Lituania 6
MD - Moldavia 6
PE - Perù 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
ET - Etiopia 5
GR - Grecia 5
IL - Israele 5
JO - Giordania 5
KH - Cambogia 5
TH - Thailandia 5
BG - Bulgaria 4
KG - Kirghizistan 4
OM - Oman 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EU - Europa 3
HU - Ungheria 3
KE - Kenya 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
RS - Serbia 3
AU - Australia 2
BY - Bielorussia 2
DK - Danimarca 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MU - Mauritius 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
PS - Palestinian Territory 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
IS - Islanda 1
Totale 11.080
Città #
Singapore 1.184
Chandler 543
Hong Kong 506
Dublin 438
San Jose 309
Ashburn 265
Jacksonville 255
San Mateo 228
Boardman 178
Perugia 168
Santa Clara 166
Moscow 130
Seoul 127
Lauterbourg 108
Medford 107
Wilmington 107
Princeton 106
The Dalles 103
Dong Ket 94
Beijing 93
Ann Arbor 89
Altamura 75
Los Angeles 70
Andover 59
Ho Chi Minh City 56
New York 56
Munich 52
Lawrence 49
Piscataway 49
Bucharest 48
Des Moines 46
São Paulo 43
Hanoi 38
Falls Church 33
Dearborn 32
Vienna 31
Council Bluffs 28
Helsinki 28
Norwalk 28
Orem 28
Shanghai 26
Tokyo 26
Bologna 25
Saint Petersburg 25
Redmond 24
Montreal 22
Rio de Janeiro 20
Brussels 19
Turku 19
Warsaw 19
Amsterdam 18
Seongnam-si 18
Woodbridge 18
Stockholm 16
Boston 15
Chennai 15
Falkenstein 15
Frankfurt am Main 15
London 15
Dallas 14
Houston 14
Phoenix 14
Baghdad 13
Brooklyn 13
Chicago 13
Izmir 13
Johannesburg 13
Da Nang 12
Brasília 11
Nuremberg 11
Olomouc 11
Redwood City 11
San Francisco 11
Tashkent 11
Denver 10
Milan 10
Ankara 9
Atlanta 9
Cebu City 9
Dhaka 9
Groningen 9
Manchester 9
Mumbai 9
Parma 9
Philadelphia 9
Rome 9
Columbus 8
Haiphong 8
Incheon 8
Istanbul 8
Cairo 7
Glasgow 7
Guangzhou 7
Lahore 7
Quito 7
Riyadh 7
Seodaemun-gu 7
Toronto 7
Auburn Hills 6
Belo Horizonte 6
Totale 6.918
Nome #
An HMGB1/RAGE/p38 MAPK/Myogenin Axis Modulates Pax7 Expression in Myoblasts by Both Transcriptional and Post-Transcriptional Mechanisms 177
Oxidative stress-induced S100B accumulation converts myoblasts into brown adipocytes via an NF-κB/YY1/miR-133 axis and NF-κB/YY1/BMP-7 axis 150
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 146
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 145
RAGE in the pathophysiology of skeletal muscle. 144
Differential expression of S100B protein and RAGE in young and aged human satellite cells. 141
S100B protein regulates myoblast and macrophage functions in skeletal muscle regeneration 138
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 136
A braking circuit between pathogen- and danger-sensing signaling pathways restrains lung inflammation: role of S100B protein, RAGE and Toll-like receptors. 136
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 135
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 134
Amphoterin-induced myogenic differentiation of RAGE-transfected rhabdomyosarcoma TE671 cells 133
Activation of RAGE in myoblasts and rhabdomyosarcoma cells results in downregulation of Pax7 expression 133
Cellular and molecular mechanisms of sarcopenia: the S100B perspective 133
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 133
Equisetum arvense standardized extract hinders age-related sarcopenia 132
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 131
Natural products to counteract muscle atrophy 131
RAGE signalling in myoblasts and embryonal rhabdomyosarcoma cells represses Pax7 expression via p38 MAPK-dependent induction of myogenin. 128
Aged vs young human satellite cells: altered expression of S100B and RAGE, and defective ability in conditioning the medium contribute to impaired myogenic potential. 128
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 127
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 126
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 125
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control 125
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 122
Amphoterin stimulates myogenesis and counteracts the anti-myogenic factors, bFGF and S100B, via RAGE binding 121
S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond 120
Hypoxia Promotes Danger-mediated Inflammation via Receptor for Advanced Glycation End Products in Cystic Fibrosis 120
Implication of RAGE and Amphoterin in Myogenesis 118
RAGE expression in rhabdomyosarcoma cells results in reduced proliferation, migration, and invasiveness in vitro and tumor growth in vivo 118
Different intrinsic properties of young and aged human satellite cells. 115
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite 113
Appropriate levels of extracellular S100B protein in injured muscle are required for correct muscle regeneration. 111
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 106
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 105
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 105
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 104
RAGE engagement in myoblasts modulates proliferation, apoptosis, adhesiveness, migration and invasiveness 104
Young and Aged Human Muscle Satellite Cells Show Differential Expression of S100B Protein and RAGE. 104
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 104
S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner 103
Causes of elevated serum levels of S100B protein in athletes 102
RAGE signaling in myoblasts and rhabdomyosarcoma cells causes downregulation of Pax7 expression via p38 MAPK activation and upregulation of myogenin expression 101
Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients 101
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 101
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 100
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation 99
S100B protein in tissue development, repair and regeneration 99
Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy 99
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 99
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 99
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 98
Caveolins and cavins in muscle-derived tumours. 98
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 97
Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness 96
Effects of deletion of RAGE in muscle regeneration: preliminary observations. 95
S100B protein differentially regulates myoblast differentiation via direct binding to RAGE and bFGF-mediated activation of FGFR1 in low-density and high-density cultures, respectively 94
Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. 94
Functions of S100 proteins 94
Opposing regulatory roles of S100B and amphoterin in myogenic differentiation: RAGE-dependence of amphoterin stimulatory effects vs. RAGE-independence of S100B inhibitory effects 93
Complex regulatory effects of extracellular S100B on myoblast differentiation: S100B activates quiescent myoblats and satellite cells 92
S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration 92
The receptor RAGE: a potential molecular target in cancer cachexia 92
Reductive stress in striated muscle cells 92
S100B's double life: Intracellular regulator and extracellular signal. 90
S100 proteins in obesity: liaisons dangereuses 90
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 90
RAGE-independence of S100B inhibition of myogenic differentiation and myotube formation 90
Functional inactivation of RAGE in myoblasts results in tumor formation 88
Molecular mechanism of S100B-dependent inhibition of myoblast differentiation 88
Elucidating the mechanism of S100B-dependent regulation of myoblast differentiation. 87
Spatiotemporal regulation of Toll-like receptors and RAGE signaling pathways by S100B protein restrains inflammation 87
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 83
Delayed Muscle Regeneration in RAGE-/- Skeletal Muscles. 83
Mechanism of S100B-dependent inhibition of myoblast differentiation 82
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo 82
S100B protein in skeletal muscle regeneration: regulation of myoblast and macrophage functions 82
S100B activates quiescent myoblasts and satellite cells 81
Enforced expression of RAGE in rhabdomyosarcoma cells result in reduced proliferation, migration, and invasiveness in vitro, activation of a myogenic program, and reduced tumor growth in vivo. 81
Potential role of S100B protein in myogenesis and skeletal muscle regeneration 80
S100B-dependent inhibition of myoblast differentiation: molecular mechanism 79
Differential involvement of RAGE and FGFR1 in S100B effects on myoblast differentiation 79
HMGB1/RAGE modulates Pax7 expression in myoblasts via p38 MAPK-dependent upregulation of myogenin. 79
Differential engagement of RAGE and FGFR1 in muscle satellite cells by S100B protein: involvement of RAGE in satellite cell activation and of FGFR1 on satellite cell expansion. 79
S100B causes apoptosis in myoblasts and inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 78
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 77
The many faces of S100B protein: when an extracellular factor inactivates its own receptor and activates another one. 77
S100B protein accelerates the activation of quiescent myoblasts and muscle satellite cells. 76
RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth 76
S100B protein restrains inflammation via spatiotemporal regulation of pathogen- and danger-sensing signaling pathways. 76
Effects of RAGE expression in rhabdomyosarcoma cells 75
Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma 75
S100B inhibits myoblast differentiation via activation of a Ras-MEK-ERK1/2 signaling pathway 75
RAGE modulates myoblast proliferation, apoptosis, migration and invasiveness 74
S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 74
S100B activates muscle satellite cells via RAGE engagement 73
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 73
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer 71
RAGE transduces antiproliferative, pro-apoptotic and anti-tumor signals in myoblasts 71
Re-expression of RAGE in damaged skeletal muscles: RAGE-/- mice show delayed muscle regeneration 71
Totale 10.259
Categoria #
all - tutte 44.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.212


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021204 0 0 0 0 0 0 0 0 0 18 75 111
2021/2022938 7 168 26 43 33 20 16 264 19 44 110 188
2022/20231.620 134 273 28 131 133 184 2 76 571 4 60 24
2023/2024737 43 70 29 31 15 18 211 23 80 16 87 114
2024/20252.294 55 203 165 106 297 109 203 208 358 122 340 128
2025/20263.894 267 220 181 537 548 413 739 233 457 299 0 0
Totale 11.356